KR102676274B1 - 세레브로리신의 용도 - Google Patents
세레브로리신의 용도 Download PDFInfo
- Publication number
- KR102676274B1 KR102676274B1 KR1020207007069A KR20207007069A KR102676274B1 KR 102676274 B1 KR102676274 B1 KR 102676274B1 KR 1020207007069 A KR1020207007069 A KR 1020207007069A KR 20207007069 A KR20207007069 A KR 20207007069A KR 102676274 B1 KR102676274 B1 KR 102676274B1
- Authority
- KR
- South Korea
- Prior art keywords
- cerebrolysin
- composition
- cardasil
- treated
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17188180.8A EP3449931B1 (en) | 2017-08-28 | 2017-08-28 | Use of cerebrolysin |
| EP17188180.8 | 2017-08-28 | ||
| PCT/EP2018/073106 WO2019042983A1 (en) | 2017-08-28 | 2018-08-28 | USE OF CERBROLYSINE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200045503A KR20200045503A (ko) | 2020-05-04 |
| KR102676274B1 true KR102676274B1 (ko) | 2024-06-18 |
Family
ID=59745228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207007069A Active KR102676274B1 (ko) | 2017-08-28 | 2018-08-28 | 세레브로리신의 용도 |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020198037A1 (en) * | 2019-03-25 | 2020-10-01 | The University Of Vermont | Methods to promote cerebral blood flow in the brain |
| EP4114843B1 (en) | 2020-07-13 | 2023-08-16 | EVER Neuro Pharma GmbH | Method for producing a mammalian brain protein hydrolysate |
| KR20240159455A (ko) * | 2021-06-02 | 2024-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE154608T1 (de) | 1990-04-12 | 1997-07-15 | Ebewe Arzneimittel | Verwendung einer mischung von peptiden and aminosäuren für die prophylaxis oder behandlung von dementia |
| EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
-
2017
- 2017-08-28 PL PL17188180T patent/PL3449931T3/pl unknown
- 2017-08-28 ES ES17188180T patent/ES2767070T3/es active Active
- 2017-08-28 EP EP17188180.8A patent/EP3449931B1/en active Active
-
2018
- 2018-08-28 ES ES18759322T patent/ES2901508T3/es active Active
- 2018-08-28 CN CN201880055542.5A patent/CN111050780B/zh active Active
- 2018-08-28 AU AU2018326339A patent/AU2018326339A1/en not_active Abandoned
- 2018-08-28 CA CA3073991A patent/CA3073991A1/en active Pending
- 2018-08-28 UA UAA202001881A patent/UA129400C2/uk unknown
- 2018-08-28 MX MX2020002267A patent/MX2020002267A/es unknown
- 2018-08-28 PL PL18759322T patent/PL3675879T3/pl unknown
- 2018-08-28 US US16/642,307 patent/US12589118B2/en active Active
- 2018-08-28 EP EP18759322.3A patent/EP3675879B1/en active Active
- 2018-08-28 EA EA202090108A patent/EA202090108A1/ru unknown
- 2018-08-28 JP JP2020512835A patent/JP7281450B2/ja active Active
- 2018-08-28 KR KR1020207007069A patent/KR102676274B1/ko active Active
- 2018-08-28 WO PCT/EP2018/073106 patent/WO2019042983A1/en not_active Ceased
-
2020
- 2020-01-09 HR HRP20200031TT patent/HRP20200031T1/hr unknown
- 2020-02-26 PH PH12020500376A patent/PH12020500376A1/en unknown
Non-Patent Citations (3)
| Title |
|---|
| BMC Medicine, 제15권, 논문번호 41 (2017. 2. 24.) |
| Neurol. Sci., 제34권, 제4호, 제553-556면 (2012. 8. 10.) |
| Ning Chen 등, "Cerebrolysin for vascular dementia", Cochrane Database Syst. Rev., 제1호, 논문번호 CD008900 (2013. 1. 31.) |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019042983A1 (en) | 2019-03-07 |
| JP2020531568A (ja) | 2020-11-05 |
| US20200376040A1 (en) | 2020-12-03 |
| PH12020500376A1 (en) | 2020-12-07 |
| ES2901508T3 (es) | 2022-03-22 |
| CA3073991A1 (en) | 2019-03-07 |
| AU2018326339A1 (en) | 2020-03-05 |
| EP3449931A1 (en) | 2019-03-06 |
| EP3675879A1 (en) | 2020-07-08 |
| CN111050780A (zh) | 2020-04-21 |
| CN111050780B (zh) | 2023-11-03 |
| JP7281450B2 (ja) | 2023-05-25 |
| PL3449931T3 (pl) | 2020-06-01 |
| UA129400C2 (uk) | 2025-04-16 |
| MX2020002267A (es) | 2020-10-22 |
| EP3675879B1 (en) | 2021-09-15 |
| EA202090108A1 (ru) | 2020-03-31 |
| ES2767070T3 (es) | 2020-06-16 |
| HRP20200031T1 (hr) | 2020-03-20 |
| KR20200045503A (ko) | 2020-05-04 |
| PL3675879T3 (pl) | 2022-02-14 |
| US12589118B2 (en) | 2026-03-31 |
| EP3449931B1 (en) | 2019-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9480658B2 (en) | Modulation of synaptic maintenance | |
| Ma et al. | Propofol attenuates inflammatory damage via inhibiting NLRP1-Casp1-Casp6 signaling in ischemic brain injury | |
| Broussalis et al. | Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies | |
| US12589118B2 (en) | Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation | |
| Zhang et al. | Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis | |
| HK40026040B (en) | Cerebrolysin for use in the treatment of cadasil | |
| EA040978B1 (ru) | Применение церебролизина | |
| Chen et al. | Exploring the protective effects of Qiju granule in a rat model of dry age-related macular degeneration | |
| Hayes | Cellular Mechanisms of IGF-1 Neuroprotection After Ischemic Stroke | |
| Noll | Spatiotemporal Neuroprotection and Early Regeneration after Ischemic Stroke with Neuregulin-1 Treatment | |
| Czapski et al. | Genetic inactivation of poly (ADP-ribose) polymerase and endothelial nitric oxide synthase prevents energy failure and oxidative damage in the mouse brain during septic shock | |
| Impairment et al. | Diffusion Tensor Mr Imaging for Evaluation of Fronto-Subcortical Neural Pathway Changes in Parkinson's Disease With Dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200310 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210810 Comment text: Request for Examination of Application |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240410 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240613 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240614 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |